Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CTSC | P53634 | 2/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.51 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135745 | 1.00 | NPC1 (0.67) | NPC1RAB9ALMNACTSCALPI | |
| SCHEMBL30573673 | 1.00 | NPC1 (0.67) | NPC1RAB9ALMNACTSCALPI | |
| SCHEMBL20474571 | 0.93 | ACACB (0.61) | NPC1RAB9ALMNACTSCCYP3A4 | |
| SCHEMBL18554018 | 0.93 | ACACB (0.61) | NPC1RAB9ALMNACTSCCYP3A4 | |
| SCHEMBL20474615 | 0.93 | ACACB (0.61) | NPC1RAB9ALMNACTSCCYP3A4 | |
| SCHEMBL23463558 | 0.92 | LTA4H (0.59) | NPC1RAB9ALMNACTSCALPI | |
| SCHEMBL22803631 | 0.92 | LTA4H (0.59) | NPC1RAB9ALMNACTSCALPI | |
| SCHEMBL974013 | 0.90 | NPC1 (0.63) | NPC1RAB9ALMNACTSCALPI | |
| SCHEMBL24931056 | 0.90 | NPC1 (0.63) | NPC1RAB9ALMNACTSCALPI | |
| SCHEMBL10195699 | 0.90 | NPC1 (0.63) | NPC1RAB9ALMNACTSCALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723305-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7718619-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-7713936-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100105781-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2010-04-29 | — | — | US | disclosed |
| US-7700561-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7687467-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687466-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7105486-B2 | Administering L-lysine-d-amphetamine; attention deficit hyperactivity disorder; decreasing the bioavailability of amphetamine by intravenous or intranasal administration, further limiting their abuse liability. | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1675555-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | New River Pharmaceuticals Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006052880-A2 | SYNERGISTIC EFFECTS OF COMBINED ADMINISTRATION OF MIRTAZAPINE AND A STIMULANT COMPOUND | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100136-A1 | Synergistic effects of combined administration of mirtazapine and a stimulant compound | SHIRE LLC | 2006-05-11 | — | — | US | disclosed |
| EP-1644019-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | New River Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005032474-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000334-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | COMT, CYP3A5, SLC6A2 | NPC1 73/4885RAB9A 3013/4885LMNA 2951/4885 |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | COMT, KDM6B, KDM5B | NPC1 137/4885RAB9A 2367/4885LMNA 1203/4885 |
| US-20100105781-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | COMT, KDM6B, KDM5B | NPC1 137/4885RAB9A 2367/4885LMNA 1203/4885 |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885LMNA 3050/4885 |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885LMNA 3050/4885 |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | DNPEP, OGFR, OPRL1 | NPC1 3556/4885RAB9A 2367/4885LMNA 3671/4885 |
| US-20060100136-A1 | Synergistic effects of combined administration of mirtazapine and a stimulant compound | SLC6A4, HTR5A, HTR4 | NPC1 738/4885RAB9A 1807/4885LMNA 3986/4885 |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885LMNA 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.